Elekta (OTCMKTS:EKTAY) Posts Quarterly Earnings Results

Key Points

• Elekta reported a quarterly earnings per share (EPS) of $0.03 with a net margin of 1.15% and a return on equity of 11.55%.
• The company's stock opened at $5.12, with a market cap of $1.89 billion and a price-to-earnings ratio of 102.42.
• Analysts have rated Elekta's stock as a "hold," with Danske recently downgrading their recommendation.

Elekta (OTCMKTS:EKTAY - Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.03 EPS for the quarter, Zacks reports. Elekta had a return on equity of 11.55% and a net margin of 1.15%.

Elekta Stock Performance

Shares of EKTAY stock opened at $5.12 on Thursday. The stock's 50-day moving average is $4.99 and its two-hundred day moving average is $5.18. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.86 and a current ratio of 1.09. Elekta has a 1 year low of $4.36 and a 1 year high of $7.13. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of 102.42 and a beta of 1.19.

Analyst Upgrades and Downgrades

Separately, Danske cut Elekta to a "hold" rating in a research note on Tuesday, June 3rd. Two equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has an average rating of "Hold".

Elekta Company Profile

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.